Frequency of epistaxis and telangiectasia in patients with hereditary hemorrhagic telangiectasia (HHT) in comparison with the general population: Curaçao diagnostic criteria revisited.

Curaçao criteria Diagnostic criteria Epistaxis Hereditary hemorrhagic telangiectasia Telangiectasia

Journal

Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831

Informations de publication

Date de publication:
08 2023
Historique:
received: 08 12 2022
revised: 16 04 2023
accepted: 18 04 2023
medline: 7 8 2023
pubmed: 1 5 2023
entrez: 1 5 2023
Statut: ppublish

Résumé

The Curaçao criteria are well-established diagnostic criteria for hereditary hemorrhagic telangiectasia (HHT), but they lack details regarding a predictive presentation of epistaxis and telangiectasias. This study collects and compares data in HHT and population cohorts to inform the application of these criteria. In-person interviews regarding epistaxis and targeted examination for telangiectases in a general population cohort (n = 204) and an HHT cohort (n = 432) were conducted. Frequency of epistaxis, rather than intensity or duration, was the best discriminator of HHT. A cutoff of ≥4 nosebleeds per year alone yielded a diagnostic sensitivity of 97%, and specificity of 84%. The mean number of telangiectases at the sites investigated was 0.4 in the general population cohort and 26.5 in the HHT cohort. The most distinctive sites for telangiectases in HHT were lips and palmar fingers, whereas telangiectases of the face and dorsum of the hand were comparable in both cohorts. We propose that the Curaçao criteria be modified to include the following cutoffs: (1) epistaxis frequency of ≥4 nosebleeds per year and (2) telangiectasia count of at least 2 in characteristic locations (palmar aspect of fingers, lips, and oral cavity), and that cutaneous telangiectases at other sites not be considered relevant for diagnostic purposes.

Identifiants

pubmed: 37125633
pii: S1098-3600(23)00878-X
doi: 10.1016/j.gim.2023.100865
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

100865

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR003142
Pays : United States

Informations de copyright

Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Conflict of Interest The authors declare no conflicts of interest.

Auteurs

Jamie McDonald (J)

Department of Pathology, University of Utah, Salt Lake City, UT.

Jenna Kornish (J)

Department of Genetics, Stanford University, Stanford, CA.

David A Stevenson (DA)

Department of Pediatrics, Division of Medical Genetics, Stanford University, Stanford, CA.

Andrea Hanson-Kahn (A)

Department of Genetics and Division of Medical Genetics, Stanford University, Stanford, CA.

Heather Balch (H)

Department of Internal Medicine, University of Utah, Salt Lake City, UT.

John James (J)

University of Utah School of Medicine, Salt Lake City, Utah.

Hetanshi Naik (H)

Department of Genetics, Stanford University, Stanford, CA.

Kevin J Whitehead (KJ)

Division of Cardiovascular Medicine, Department of Medicine, HHT Center, University of Utah, Salt Lake City, UT. Electronic address: kevin.whitehead@hsc.utah.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH